Labat AfricaJSE:LAB EBIT per Share is R0.15 as of Nov. 2025. The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, Labat Africa ranks better than 76.76% on this metric.
Labat Africa's EBIT per Share for the
six
months ended in Nov. 2025 was R0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2025 was R0.15.
During the past 3 years, the average EBIT per Share Growth Rate was 27.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -4.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Labat Africa's EBIT per Share or its related term are showing as below:
JSE:LAB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -114.8 Med: -16.9 Max: 47.7
Current: 27.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Labat Africa was 47.70% per year. The lowest was -114.80% per year. And the median was -16.90% per year.
JSE:LAB's 3-Year EBIT Growth Rate is ranked better than 76.76% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs JSE:LAB: 27.20
Labat Africa's EBIT for the
six
months ended in Nov. 2025 was R96.9 Mil.
Labat Africa (JSE:LAB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Labat Africa EBIT per Share Related Terms
Labat Africa EBIT per Share Historical Data
* Premium members only.
The historical data trend for Labat Africa's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was R0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labat Africa (JSE:LAB) has a EBIT per Share of R0.15 as of Nov. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #188 out of 809 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is Labat Africa's EBIT per Share too high?
Labat Africa's current EBIT per Share is R0.15. Based on the distribution chart, Labat Africa ranks #188 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #188 out of 809 companies for EBIT per Share. This places Labat Africa in the top 23% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current EBIT per Share is R0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.22, compared to a current price of R0.05 — trading 77.3% below its estimated fair value. The current EBIT per Share is R0.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current EBIT per Share is R0.15 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 